This paper reports the results of a clinical trial of the fibrinolytic inhibitor epsilon-aminocaproic acid (E.A.C.A.) in a group of patients with high-grade haemophilia. There is evidence to suggest that the coagulation system and the fibrinolytic enzyme system may be in a state of dynamic equilibrium ; the E.A.C.A. was given in an attempt to displace the balance in favour of haemostasis.
The main components of the fibrinolytic enzyme system are plasminogen, plasmin, activators, and inhibitors. Plasminogen, a naturally occurring plasma globulin, is converted by activators to plasmin, an enzyme which can digest many proteins, including fibrinogen and fibrin, prothrombin, factor V, and antihaemophilic globulin. Under physiological circumstances it is thought that natural inhibitors in the plasma restrict plasmin to digestion of fibrin, but in pathological fibrinolytic (hyperplasminaemic) states plasma proteins, including fibrinogen and antihaemophilic globulin, are digested. Activators of plasminogen include a plasma activator, trace quantities of which are probably responsible for physiological fibrinolytic activity, a urinary activator named urokinase, and activators of bacterial origin-for example, streptokinase. E.A.C.A., a potent competitive inhibitor of plasminogen activation (Alkiaersig et al., 1959) , was first used in man by Sherry et al. (1959) , who found it effective in inhibiting plasma fibrinolytic activity induced by a variety of plasminogen activators. The value of E.A.C.A. in the treatment of pathological fibrinolytic states has recently been reviewed by McNicol and Douglas (1964) , who also discuss the pharmacology and toxicity of E.A.C.A. E.A.C.A., a synthetic amino-acid which closely resembles lysine in structure, is rapidly absorbed when taken by mouth. Peak plasma levels are found about two hours after a single oral dose. Urinary excretion is also rapid, the greater part of a single dose being recovered unchanged in the urine in 12 hours. The action of E.A.C.A. as an inhibitor of plasminogen activation is seen with plasma concentrations above 1 mg./100 ml.
The Steiger et al. (1962) and Barkhan (1964) have also reported successful control of haematuria in three patients and one patient respectively with haemophilia, without any adverse effects on renal function. Abe et al. (1962) and Reid et al. (1964) fibrinolytic activity. It is reasonable to suppose that administration of a potent antifibrinolytic agent might displace the equilibrium of the coagulation-fibrinolytic systems in favour of haemostasis by protecting any clots which form from physiological fibrinolytic processes. Further, E.A.C.A. might conceivably protect plasma coagulation factors, such as factor V and antihaemophilic globulin (factor VIII), from digestion by low levels of plasmin which may be in part responsible for physiological turnover of these clotting factors. In view of these considerations, and of the favourable reports in the literature, it was thought worth while to embark on a controlled clinical and laboratory study of E.A.C.A. in a group of highgrade haemophiliacs.
Materials and Methods

Design of the Trial
Ten haemophiliacs were chosen, each with a history of severe spontaneous bleeding episodes, and with a level of antihaemophilic globulin (factor VIII) of less than 1 %, whose ages ranged from 12 to 41 years (with a mean of 20.3 years).
A random allocation of E.A.C.A., dissolved in a syrupy vehicle, and a placebo (vehicle only) was made. The subjects received the active agent (in a dose of 3.3 g. orally four times daily with meals) for six weeks, followed by the placebo preparation (or vice versa) for the same period in identical dosage, with an intervening six-week phase during which no medication was given. The trial was conducted in a double-blind manner, the subsequent clinical observations being made by the same individual throughout. The key to the identity of the preparations was not broken until the conclusion of the trial.
During each phase of six weeks the patients attended twice weekly at an out-patient clinic, and were questioned regarding the occurrence of bleeding episodes. Any haemorrhagic lesions present were assessed clinically and awarded a score ranging from 1 to 4 according to the size and severity of the lesion: the total score for each patient for each of the six-week periods was calculated.
At the beginning of the trial, and at intervals of three weeks thereafter, citrated and heparinized samples of venous blood were collected from each subject for estimation of haemoglobin, white-cell count, platelets, and erythrocyte sedimentation rate, and for liver-function tests. In addition, plasma samples were assayed for antihaemophilic globulin (factor VIII), plasminogen, and fibrinogen levels. Urokinase-sensitivity tests were performed, and plasma electrophoresis was carried out.
An E.C.G. (standard limb leads) was performed on each patient at the start of the trial and at the termination of each six-week phase.
Plasminogen assays were carried out by the caseinolytic technique of Remmert and Cohen (1949) as modified by Alkjaersig et al. (1959) .
Fibrinogen assays were performed by the method of Ratnoff and Menzie (1951) as modified by Alkjaersig (1960) .
Antihaemophilic globulin (factor VIII) assays were performed by a method which is dependent on the clotting-time of recalcified plasma from patients with severe haemophilia, which is maximally "contact activated " by kaolin. Cephalin, prepared as described by Bell and Alton (1954) , was added to the substrate system.
Urokinase-sensitivity tests were carried out as described by McNicol et al. (1963) . To 0.2 ml. of citrated plasma were added 80 p.d. of urokinase solution (500 units/ml.) and thrombin (0.1 ml. of a 20 N.I.H. unit/ml. solution). The plasma was incubated at 370 C., and the times for complete clot lysis were measured. Following the reasoning discussed in the assignment of units to euglobulin lysis times (Sherry and Alkjaersig, 1957) , activity in the urokinase-sensitivity test results was expressed in arbitrary units, a lysis time of 10 minutes being assigned 1 unit of activity. The shorter the lysis time induced by urokinase the higher the units of activity-that is, the presence of an inhibitor of activation would be associated with a small number of units of activity.
Urokinase, a purified preparation isolated from the urine of normal males, was made available by Leo Laboratories Ltd.
Epsilon Table III gives the results of clotting and lytic factor assays during the trial. E.A.C.A. had no effect upon the level of antihaemophilic globulin (factor VIII) in any of the subjects Results Table I shows the total bleeding events and cumulative scores recorded for the 10 subjects during each of the three six-week periods of observation. The relative numbers of spontaneous and traumatically induced bleeding episodes are also recorded. The observed differences of the scores between E.A.C.A. and placebo periods just fail to achieve the conventionally accepted level of statistical significance (t=2.137 and 0.5>P>0.1; The consistent failure of E.A.C.A. to cause a rise in plasma levels of antihaemophilic globulin (factor VIII) suggests that physiological levels of plasma fibrinolytic activity are not responsible for destruction of antihaemophilic globulin in vivo in high-grade haemophiliacs, and the improvement in haemostasis seen in the present trial cannot be attributed to protection of antihaemophilic globulin from proteolysis by plasmin. Further, the failure to see a rise in plasma fibrinogen levels suggests that plasma fibrinogen turnover is not mediated through plasma fibrinolytic activity. Moreover, Rausen et al. (1961) , using fibrinogen labelled with radioactive iodine, have shown that fibrinogen turnover is normal in patients with severe haemophilia, suggesting that in vivo clotting is not a major factor in the fibrinogen turnover; and it would therefore appear that turnover of fibrinogen is produced by some biochemical mechanism other than digestion by plasmin or intravascular clotting. a,-Globulin () a2-Globulin (%) 1-Globulin (%) .... No direct estimation of plasma E.A.C.A. levels was made, but as measured by the resistance of the plasma to lysis by urokinase in the urokinase-sensitivity test, marked antifibrinolytic activity was imparted to the plasma by the dosage schedule of E.A.C.A. which was employed in the trial. From previous studies (McNicol et al., 1962 ) the dosage employed in the present trial, 3.3 g. six-hourly, might have been expected to achieve plasma E.A.C.A. levels fluctuating between 2 and 10 mg./100 ml., levels adequate to produce inhibition of plasma plasminogen activation varying from detectable at the lower levels to marked at the upper levels.
Toxicity and Side-effects of E.A.C.A.
With regard to the fundamental action of E.A.C.A. upon the plasminogen-plasmin system, and the accepted role of the latter in maintaining a patent vascular tree, the possibility exists that E.A.C.A. might cause vascular occlusion by inhibiting the lysis of intravascular fibrin. This potential hazard has been the subject of several published reports. Andersson et al. (1962) found that in a trial of 50 patients given E.A.C.A. following prostatectomy 9 had evidence of thrombosis or embolism, and that 5 out of 25 control patients also had post-operative thromboembolic complications. McNicol et al. (1961b) , in a trial of E.A.C.A. given to 23 patients after prostatectomy, noted vascular occlusion in two patients some hours after administration of E.A.C.A. in one patient and 10 days later in the other. There are other reports of vascular occlusion following E.A.C.A. therapy from Naeye (1962) and Fletcher et al. (1962a) . In the present trial, as might be anticipated in patients with grossly deficient haemostatic mechanisms, there was no clinical evidence of the occurrence of vascular occlusive episodes at any time in any of the subjects during E.A.C.A. therapy.
The serial haematological and biochemical estimations performed during the trial gave no evidence of marrow depression or liver dysfunction attributable to E.A.C.A.
Reported side-effects of E.A.C.A. have included hypotension and dizziness (Andersson et al., 1962 ; Beck et al., 1963) , abdominal discomfort, conjunctival suffusion, and nasal stuffiness (McNicol et al., 1962) .
In the present study only two patients experienced abnormal symptoms that might possibly be attributed to E.A.C.A. One subject complained of nasal congestion and headache, while a second experienced several episodes of mild diarrhoea and abdominal discomfort. In neither case were symptoms sufficiently incapacitating to require withdrawal of the drug.
As has been reported by McNicol et al. (1962) , E.A.C.A., in the isolated rat-diaphragm preparation, inhibits the incorporation into protein of lysine, which it structurally resembles, and it is possible, especially in growing children, that long-term administration of E.A.C.A. might have deleterious effects, not seen in the present trial, due to interference in this or other ways with amino-acid metabolism. Accordingly, the much more potent (Dubber et al., 1964) and in animal studies less toxic Fig. 1, A The lower rates in Scotland might be due to the larger proportion of the population living under rural or semi-rural conditions. In fact the difference in urbanization between the two countries is not as great as might be expected, owing to the concentration of population in Scotland in the Forth-Clyde industrial belt. In Scotland in 1959, 45.8% of the population lived in small burghs (towns) or landward (rural) areas. In the same year in England and Wales the proportion was 40.6%. A priori it seems unlikely that a difference of 5.2% could entirely account for the large difference in the bronchitis mortality rates, but this possibility has been examined.
The mortality rates in the different parts of the two countries were compared, following the Registrar-Generals'
